Fox Run Management L.L.C. Buys Shares of 27,796 AnaptysBio, Inc. $ANAB

Key Points

• Fox Run Management L.L.C. has acquired 27,796 shares of AnaptysBio, Inc. during the first quarter, amounting to approximately $517,000, giving it a 0.09% ownership in the company.
• Insider trading activity at AnaptysBio included Director Hollings Renton selling 20,925 shares, a significant 80.82% decrease in his position, valued at $493,202.25.
• Analysts have recently raised their price targets for AnaptysBio, with JPMorgan Chase increasing their estimate from $42.00 to $80.00, reflecting growing optimism about the company's performance.

Fox Run Management L.L.C. acquired a new position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 27,796 shares of the biotechnology company's stock, valued at approximately $517,000. Fox Run Management L.L.C. owned 0.09% of AnaptysBio as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. US Bancorp DE increased its stake in shares of AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 979 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of AnaptysBio by 9,778.9% in the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 1,531 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in shares of AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 5,360 shares in the last quarter.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of AnaptysBio stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director directly owned 4,965 shares in the company, valued at $117,025.05. The trade was a 80.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 33.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ANAB has been the subject of several recent research reports. HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. Wedbush lifted their target price on shares of AnaptysBio from $40.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. lifted their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Guggenheim reiterated a "buy" rating and issued a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. Finally, UBS Group reaffirmed a "neutral" rating and set a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, AnaptysBio presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.13.

AnaptysBio Stock Performance

NASDAQ ANAB traded down $0.14 on Friday, hitting $20.22. The stock had a trading volume of 257,922 shares, compared to its average volume of 483,118. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $40.70. The company has a market capitalization of $566.16 million, a price-to-earnings ratio of -4.51 and a beta of -0.20. The firm has a 50-day moving average of $23.64 and a 200-day moving average of $20.65.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The business had revenue of $22.26 million during the quarter, compared to analyst estimates of $11.55 million. As a group, research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.